1. Signaling Pathways
  2. Anti-infection
  3. Reverse Transcriptase

Reverse Transcriptase

Reverse transcriptases (RTs) are enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. Reverse transcriptases (RTs) use an RNA template and a short primer complementary to the 3' end of the RNA to direct the synthesis of the first strand cDNA.

Nucleoside reverse transcriptase inhibitors (NRTIs) block reverse transcriptase (an HIV enzyme). Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and block HIV reverse transcriptase. HIV uses reverse transcriptase to convert its RNA into DNA (reverse transcription). Blocking reverse transcriptase and reverse transcription prevents HIV from replicating.

Reverse Transcriptase Related Products (214):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162461
    HIV-1 inhibitor-66
    Inhibitor
    HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcription inhibitor (NNRTI). HIV-1 inhibitor-66 shows inhibitory activity against wild-type HIV-1 reverse transcriptase with an IC50 of 40 nM.
    HIV-1 inhibitor-66
  • HY-151933
    HIV-1 inhibitor-49
    Inhibitor
    HIV-1 inhibitor-49 is an orally active HIV-1 inhibitor, is a HEPT analog. HIV-1 inhibitor-49 possesses great pharmacokinetics profiles and potent non-nucleoside reverse transcriptase inhibitory activity (IC50=30 nM). HIV-1 inhibitor-49 exerts potential safety without acute toxicity in mouse model.
    HIV-1 inhibitor-49
  • HY-10572B
    (Rac)-Efavirenz
    Inhibitor
    (Rac)-Efavirenz is the isomer of Efavirenz (HY-10572). Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.
    (Rac)-Efavirenz
  • HY-117725
    S-2720
    Inhibitor
    S-2720 is a potent inhibitor of both immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) and HIV-1 replication. The binding sites of S-2720 and the nonnucleoside compounds overlap. The small pocket in the p66 subunit-BI-RG-587 (HY-10570) complex is most likely the target of S-2720. S-2720 is a quinoxaline derivative, which is promising for research of HIV-1 infection.
    S-2720
  • HY-B0250S1
    Lamivudine-13C,15N2,d2
    Inhibitor
    Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase.
    Lamivudine-<sup>13</sup>C,<sup>15</sup>N<sub>2</sub>,d<sub>2</sub>
  • HY-126900
    HI-253
    Inhibitor
    HI-253 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase that has demonstrated greater activity than multiple anti-HIV compounds against both resistant and sensitive HIV-1 strains.
    HI-253
  • HY-138561
    EFdA-TP
    Inhibitor
    EFdA-TP is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits HIV-1 RT with multiple mechanisms.
    EFdA-TP
  • HY-118632
    BILR 355
    Inhibitor
    BILR 355 is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI). BILR 355 is highly specific toward HIV-1 reverse transcriptase (RT). BILR 355 can be used for HIV infections research.
    BILR 355
  • HY-106155
    Amdoxovir
    Inhibitor
    Amdoxovir (DAPD) is an orally active nucleoside reverse transcriptase inhibitor. Amdoxovir is active against wild-type and NRTl-resistant viruses. Amdoxovir is the prodrug of dioxolane guanosine. Amdoxovir can be used for research of HIV/AIDS.
    Amdoxovir
  • HY-W765997
    Didanosine-13C2,15N
    Didanosine-13C2,15N (2',3'-Dideoxyinosine-13C2,15N; ddI-13C2,15N) is the 13C- and 15N-labeled labeled Didanosine (HY-B0249). Didanosine (2',3'-Dideoxyinosine; ddI) is a a potent and orally active dideoxynucleoside analogue, and also is a potent nucleoside reverse transcriptase inhibitor. Didanosine shows antiretroviral activity for HIV.
    Didanosine-<sup>13</sup>C<sub>2</sub>,<sup>15</sup>N
  • HY-B0250S
    Lamivudine-15N,d2
    Inhibitor
    Lamivudine-15N,d2 is 15N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>15</sup>N,d<sub>2</sub>
  • HY-B0116S
    Stavudine-d4
    Inhibitor
    Stavudine-d4 is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis.
    Stavudine-d<sub>4</sub>
  • HY-175351
    HIV-1-IN-83
    Inhibitor
    HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC50 of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM.
    HIV-1-IN-83
  • HY-116454
    GSK5750
    Inhibitor
    GSK5750 is a specific and potent HIV-1 reverse transcriptase ribonuclease H inhibitor with an IC50 value of 0.33 μM. GSK5750 is bound at the RNase H active site through a metalion chelation mechanism.
    GSK5750
  • HY-163362
    HIV-1 inhibitor-65
    Inhibitor
    HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC50: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase.
    HIV-1 inhibitor-65
  • HY-176169
    DC20
    Inhibitor
    DC20 is an orally active non-nucleoside reverse transcriptase inhibitor with an EC50 of 0.004 μM aganist HIV-1IIIB.
    DC20
  • HY-15350
    Trovirdine hydrochloride
    Inhibitor
    Trovirdine hydrochloride, a phenethylthiazolylthiourea (PETT) derivative, is an HIV reverse transcriptase (RT) non-nucleoside inhibitor (NNI). A novel computer model of the RT/NNI binding pocket revealed spatial gaps around Trovirdine hydrochloride's pyridyl ring. Docking studies suggested that replacing this planar ring with a nonplanar piperidinyl or piperazinyl ring could better occupy the binding pocket, enhancing anti-HIV activity. Synthesized heterocyclic compounds based on this modification demonstrated greater potency than Trovirdine hydrochloride, effectively inhibiting HIV replication at nanomolar concentrations without cytotoxicity in infected peripheral blood mononuclear cells.
    Trovirdine hydrochloride
  • HY-14266S1
    Dapivirine-d4
    Inhibitor
    Dapivirine-d4 (TMC120-d4) is deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations.
    Dapivirine-d<sub>4</sub>
  • HY-152200
    HIV-1 inhibitor-53
    Inhibitor
    HIV-1 inhibitor-53 is a dual HIV-1 protease and reverse transcriptase inhibitor. HIV-1 inhibitor-53 inhibits HIV-1 protease (PR) and reverse transcriptase (RT) activity with IC50 values of 1.93 nM and 2.35 μM, respectively. HIV-1 inhibitor-53 can be used for the research of acquired immune deficiency syndrome (AIDS).
    HIV-1 inhibitor-53
  • HY-W653961
    Tenofovir alafenamide-d5 fumarate
    Tenofovir alafenamide-d5 fumarate (GS-7340-d5 fumarate) is the deuterium labeled Tenofovir alafenamide fumarate (HY-15232A). Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
    Tenofovir alafenamide-d<sub>5</sub> fumarate